Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)

NCT04497116 is registered in ClinicalTrials.gov with Repare Therapeutics as lead sponsor.

NCT NCT04497116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04497116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
Lead sponsor
Repare Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
July 22, 2020
Completion date
June 13, 2025
Enrollment
276 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor